OverviewChartProfileKey statisticsFinancialsTechnicalNews
Derivatives
TraderScreen

Atos SE/  FR0000051732  /

Euronext - Paris
2024-11-15  5:39:40 PM Chg. +0.0227 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
0.2122EUR +11.98% 13.71 mill.
Turnover: 2.91 mill.		 0.2100Bid Size: 4,000 0.2200Ask Size: 50 23.65 mill.EUR - -
GlobeNewswire 08-28 Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
GlobeNewswire 08-21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 08-21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...
GlobeNewswire 08-20 Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Publi...
GlobeNewswire 08-14 Stevie® Awards Announce Winners in The 21st Annual International Business Awards® from Across the Gl...
GlobeNewswire 08-12 Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 07-30 HUMAN Releases The Quadrillion Report: 2024 Cyberthreat Benchmarks, Uncovers Nearly 150 Million Comp...
GlobeNewswire 07-22 Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE...
GlobeNewswire 07-02 Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
GlobeNewswire 06-28 Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combin...
GlobeNewswire 06-17 Atossa Set to Join Russell 3000® Index Effective June 28, 2024
GlobeNewswire 06-11 Pythian Welcomes Brooks Borcherding as Chief Executive Officer
GlobeNewswire 06-05 Atossa to Present at the Sidoti Small-Cap Investor Conference
GlobeNewswire 05-30 Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets
GlobeNewswire 05-28 NetLogistik Wins Partner Leadership Award from Blue Yonder
GlobeNewswire 05-28 Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...
GlobeNewswire 05-16 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire 05-15 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire 05-15 Calian Reports Record Results for the Second Quarter
GlobeNewswire 05-13 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 05-13 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing
GlobeNewswire 05-07 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
GlobeNewswire 04-29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire 04-15 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire 04-11 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference